Vickram Ramkumar

Adenosine, oxidative stress and cytoprotection.

Cisplatin up-regulates the adenosine A(1) receptor in the rat kidney.

Hsp70 in the inferior colliculus of Fischer-344 rats: effects of age and acoustic stress.

Hypertonicity inhibits lipopolysaccharide-induced nitric oxide synthase expression in smooth muscle cells by inhibiting nuclear factor kappaB.

Noise induces A1 adenosine receptor expression in the chinchilla cochlea.

Direct interaction of adenosine with the TRPV1 channel protein.

Protection against cisplatin ototoxicity by adenosine agonists.

Osmotic diuretics induce adenosine A1 receptor expression and protect renal proximal tubular epithelial cells against cisplatin-mediated apoptosis.

Activation of the adenosine A3 receptor in RAW 264.7 cells inhibits lipopolysaccharide-stimulated tumor necrosis factor-alpha release by reducing calcium-dependent activation of nuclear factor-kappaB and extracellular signal-regulated kinase 1/2.

Essential role of Rac1/NADPH oxidase in nerve growth factor induction of TRPV1 expression.

Induction of adenosine A1 receptor expression by pertussis toxin via an adenosine 5'-diphosphate ribosylation-independent pathway.

Nitric oxide serves as an endogenous regulator of neuronal adenosine A1 receptor expression.

Activation of the adenosine A1 receptor inhibits HIV-1 tat-induced apoptosis by reducing nuclear factor-kappaB activation and inducible nitric-oxide synthase.

Expression of striatal adenosine and dopamine receptors in mice deficient in the p50 subunit of NF-kappaB.

Adenosine and dopamine receptor interactions in striatum and caffeine-induced behavioral activation.

Short interfering RNA against transient receptor potential vanilloid 1 attenuates cisplatin-induced hearing loss in the rat.

Role of beta-arrestin1/ERK MAP kinase pathway in regulating adenosine A1 receptor desensitization and recovery.

Cisplatin ototoxicity and protection: clinical and experimental studies.

Adenosine A(3) receptor suppresses prostate cancer metastasis by inhibiting NADPH oxidase activity.

Transtympanic administration of short interfering (si)RNA for the NOX3 isoform of NADPH oxidase protects against cisplatin-induced hearing loss in the rat.

Lack of association of a spontaneous mutation of the Chrm2 gene with behavioral and physiologic phenotypic differences in inbred mice.

Nuclear Factor κB and Adenosine Receptors: Biochemical and Behavioral Profiling.

The design and screening of drugs to prevent acquired sensorineural hearing loss.

Resveratrol reduces prostate cancer growth and metastasis by inhibiting the Akt/MicroRNA-21 pathway.

Essential Role of NADPH Oxidase-Dependent Reactive Oxygen Species Generation in Regulating MicroRNA-21 Expression and Function in Prostate Cancer.

Adenosine receptors: expression, function and regulation.

TRPV1: A Potential Drug Target for Treating Various Diseases.

Early investigational drugs for hearing loss.

Adenosine A1 Receptor Protects Against Cisplatin Ototoxicity by Suppressing the NOX3/STAT1 Inflammatory Pathway in the Cochlea.

Tonic suppression of PCAT29 by the IL-6 signaling pathway in prostate cancer: Reversal by resveratrol.

Epigallocatechin-3-gallate, a prototypic chemopreventative agent for protection against cisplatin-based ototoxicity.

Mechanisms of Cisplatin-Induced Ototoxicity and Otoprotection.